PharmAla’s Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the…
Podcast: LSD ‘Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics’ Says MindMed’s R. Barrow
Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Robert Barrow, CEO of…
Enveric Biosciences Optimistic On Q4 And Full-Year Results: ‘Psychedelic-Inspired’ Meds For Future Growth
Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the…
Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Two separate deals hit the wires on Tuesday. One is PharmAla Biotech’s (OTC:OPTHF) with Tel Aviv University for…
Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs And More
Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items concerning the last few…
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months A new study…
Clearmind Medicine Receives Patent Approval For Its Psychedelic Based Treatment Of Binge Behaviors In China
Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health
MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
The TDR Three Takeaways:
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
Certain fungi species that spontaneously produce psilocybin, a powerful substance that activates the serotonin 5-HT2A receptor in the…